Research programme: transdermal therapeutics - Aequus Pharmaceuticals

Drug Profile

Research programme: transdermal therapeutics - Aequus Pharmaceuticals

Alternative Names: AQS 1302; AQS 1303; AQS 1304; Cannabinoid transdermal delivery system; Clobazam transdermal patch; Doxylamine/pyridoxine transdermal patch; Pyridoxine/doxylamine transdermal patch

Latest Information Update: 08 May 2017

Price : $50

At a glance

  • Originator Aequus Pharmaceuticals
  • Class Antidementias; Antiemetics; Antiepileptic drugs; Anxiolytics; Benzodiazepines; Cannabinoids; Picolines; Pyridines; Sedating antihistamines; Small molecules; Vitamins
  • Mechanism of Action Biogenic monoamine uptake modulators; Cannabinoid receptor modulators; GABA A receptor agonists; Histamine H1 receptor antagonists; Neurotransmitter stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Epilepsy; Nausea

Most Recent Events

  • 01 May 2017 Preclinical trials in Alzheimer's disease in Canada (Transdermal) before May 2017 (Aequus Pharmaceuticals website, May 2017)
  • 02 Mar 2017 Aequus Pharmaceuticals enters into a binding term sheet agreement for worldwide exclusive license of cannabinoid transdermal patch for Neurological disorders
  • 18 Nov 2016 Aequus Pharmaceuticals plans a proof-of-concept study for Nausea and Vomiting of pregnancy in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top